In the past week, PSTX stock has gone up by 28.54%, with a monthly gain of 28.54% and a quarterly surge of 9.86%. The volatility ratio for the week is 7.26%, and the volatility levels for the last 30 days are 4.69% for Poseida Therapeutics Inc. The simple moving average for the past 20 days is 24.21% for PSTX’s stock, with a 6.66% simple moving average for the past 200 days.
Is It Worth Investing in Poseida Therapeutics Inc (NASDAQ: PSTX) Right Now?
The 36-month beta value for PSTX is also noteworthy at 0.60. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PSTX is 65.08M, and at present, short sellers hold a 7.40% of that float. The average trading volume of PSTX on November 08, 2024 was 436.34K shares.
PSTX) stock’s latest price update
Poseida Therapeutics Inc (NASDAQ: PSTX)’s stock price has gone rise by 8.36 in comparison to its previous close of 2.93, however, the company has experienced a 28.54% increase in its stock price over the last five trading days. zacks.com reported 2024-11-07 that Poseida Therapeutics, Inc. (PSTX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to loss of $0.35 per share a year ago.
Analysts’ Opinion of PSTX
Many brokerage firms have already submitted their reports for PSTX stocks, with H.C. Wainwright repeating the rating for PSTX by listing it as a “Buy.” The predicted price for PSTX in the upcoming period, according to H.C. Wainwright is $15 based on the research report published on January 04, 2023 of the previous year 2023.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see PSTX reach a price target of $24. The rating they have provided for PSTX stocks is “Overweight” according to the report published on January 07th, 2022.
BTIG Research gave a rating of “Buy” to PSTX, setting the target price at $40 in the report published on May 18th of the previous year.
PSTX Trading at 15.10% from the 50-Day Moving Average
After a stumble in the market that brought PSTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.64% of loss for the given period.
Volatility was left at 4.69%, however, over the last 30 days, the volatility rate increased by 7.26%, as shares surge +27.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.30% upper at present.
During the last 5 trading sessions, PSTX rose by +29.96%, which changed the moving average for the period of 200-days by -0.93% in comparison to the 20-day moving average, which settled at $2.56. In addition, Poseida Therapeutics Inc saw -5.51% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PSTX
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.91 for the gross margin
The net margin for Poseida Therapeutics Inc stands at -1.26. The total capital return value is set at -0.6. Equity return is now at value -115.00, with -38.89 for asset returns.
Based on Poseida Therapeutics Inc (PSTX), the company’s capital structure generated 0.52 points at debt to capital in total, while cash flow to debt ratio is standing at 0.04. The debt to equity ratio resting at 1.07. The interest coverage ratio of the stock is 14.23.
Currently, EBITDA for the company is -129.5 million with net debt to EBITDA at -0.39. When we switch over and look at the enterprise to sales, we see a ratio of 4.08. The receivables turnover for the company is 7.12for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.48.
Conclusion
In summary, Poseida Therapeutics Inc (PSTX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
